BERKELEY, CA--(Marketwired - Oct 7, 2014) - Dynavax Technologies Corporation (
"We are grateful for Dino's leadership and the contributions he made to Dynavax's development as a fellow Board member and during his 15-year tenure as our CEO," said Arnold Oronsky, Ph.D., Chairman of Dynavax.
Dr. Dina added, "With the recent completion of enrollment in the Phase 3 HEPLISAV-B™ clinical trial, Dynavax has achieved yet another milestone on the path to success for the company and the people who may benefit from its products."
About Dynavax
Dynavax, a clinical-stage biopharmaceutical company, discovers and develops novel vaccines and therapeutics in the areas of infectious and inflammatory diseases and oncology. Dynavax's lead product candidate is HEPLISAV-B, a Phase 3 investigational adult hepatitis B vaccine. For more information visit www.dynavax.com.
Contact Information:
Contact:
Michael S. Ostrach
Vice President, Chief Business and Principal Financial Officer
510-665-7257